Selected press releases on key aspects of SEEK’s activities are included below for your information and interest
Antibody Treatment for HIV
Cocoa-flavoured cough medicine will be first product to market
Single vaccination effective against all influenza strains. Data to be presented at Influenza Congress 2011 USA.
90% reduction in HIV viral load demonstrated compared with normal disease progression
First potential new active cough treatment in over 50 years
Theobromine based drug close to commercialisation, has potential to address the serious need for a safer, opioid free treatment for persistent cough
First effective non-opioid treatment in two decades could be available within two years
Safety and immunogenicity in humans established
PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.
PepTcell, a drug discovery group with an innovative mid to late stage portfolio, is pleased to announce the appointment of Manfred Scheske as Chief Executive Officer of Consumer Health.
Retroscreen Virology Limited, a global leader in anti-viral research, clinical trials and experimental challenge studies, is pleased to announce that it will be participating in a clinical trial with PepTcell Limited to test Flu-v, part of a new class of influenza T cell vaccines.
PepTcell Ltd. an immunology company with a focus on the development of vaccines for the prevention and treatment of infectious diseases, announced today that it has received approval from the MHRA to commence a Phase 1b clinical trial for its novel HIV vaccine in the UK.
A method for discovering entirely new career paths for existing clinical drugs is being exploited by start-up company Tangent Reprofiling Ltd., following a deal just signed between the company, PepTcell Limited, the University of Warwick and Warwick spin-out company a2sp Ltd.
PepTcell Ltd. and Gador S.A. today announced an R&D collaboration to develop a novel T-cell vaccine for Chagas disease, a neglected tropical disease with no adequate treatment or vaccination.
Data showing how a new flu vaccine from PepTcell has the potential to protect against all strains of influenza, including pandemic and annual, has been published in this month’s European Journal of Immunology.
Previously undisclosed pre-clinical data showing how a new flu vaccine has the potential to protect against all strains of influenza, including pandemic and annual, was presented today by PepTcell, at the 2007 Options for the Control of Influenza VI Conference, in Toronto, Canada.
PepTcell Ltd. an immunology company with a focus on the development of vaccines for the prevention and treatment of infectious diseases, has started safety studies for its novel HIV-v vaccine, a vaccine which in addition to stopping HIV infection, could also be used for treating HIV.